Nymox Pharmaceutical Corp (NYMX) 2.61 $NYMX
Nymox Pharmaceutical (NYMX) Stock Higher on Positive Test Results
at The Street - Tue Jul 28, 11:44AM CDT
Nymox Pharmaceutical (NYMX) shares continue to climb on promising BPH treatment candidate results.
NYMX: 2.61 (+0.04)
Nymox July 27 Webcast of New BPH Clinical Trial Results Posted Today Online
GlobeNewswire - Tue Jul 28, 11:00AM CDT
Nymox's (NASDAQ:NYMX) July 27 webcast of news and discussion by experts of the Company's new clinical trial results can be viewed at http://limelightdc.com/clientarea/nymox_inves...r_vod.html. The link is also available at the Company's website.
NYMX: 2.61 (+0.04)
Nymox Pivotal Phase 3 NX-1207 BPH Extension Trial Successfully Meets Primary Endpoint. Company Plans to File for Regulatory Approvals for Fexapotide Triflutate (NX-1207).
GlobeNewswire - Mon Jul 27, 8:30AM CDT
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) announced today that the Company's U.S. long-term extension prospective double-blind Phase 3 BPH studies NX02-0017 and NX02-0018 of fexapotide triflutate (NX-1207) for BPH have successfully met the pre-specified primary endpoint of long-term symptomatic statistically significant benefit superior to placebo. Fexapotide showed an excellent safety profile with no evidence of drug-related short-term or long-term toxicity nor any significant related molecular side effects in the 2 studies (n=978).
NYMX: 2.61 (+0.04)
Nymox Appoints Cutler & Co. as Auditor
GlobeNewswire - Thu Jul 16, 5:03PM CDT
On July 15, 2015, the Board of Directors of Nymox Pharmaceutical Corporation (NASDAQ:NYMX) approved the engagement of Cutler & Co., LLC to serve as the Company's new independent registered public accounting firm to replace KPMG LLP. Prior to the date of Cutler's engagement, the Company has not consulted with Cutler regarding (i) the application of accounting principles to a specific completed or contemplated transaction, (ii) the type of audit opinion that might be rendered on the Company's financial statements and neither a written report was provided to the registrant nor oral advice was provided that the new accountant concluded was an important factor considered by the registrant in reaching a decision as to the accounting, auditing or financial reporting issue; or (iii) any matter that was either the subject of a disagreement.
NYMX: 2.61 (+0.04)
Nymox Announces Appointment of Erik Danielsen as CFO
GlobeNewswire - Mon Jul 13, 12:15PM CDT
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce the appointment of Erik Danielsen as Chief Financial Officer of the Company. Mr. Danielsen is a highly experienced financial analyst with special expertise in emerging health care companies, and with extensive international business knowledge.
NYMX: 2.61 (+0.04)
Benign Prostatic Hyperplasia Pipeline Report 2015 - 26 Companies & 35 Drug Profiles
M2 - Fri Jul 10, 3:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/k3hn53/benign_prostatic) has announced the addition of the "Benign Prostatic Hyperplasia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Benign Prostatic Hyperplasia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Benign Prostatic Hyperplasia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Addex Therapeutics Ltd - AmVac AG - AndroScience Corporation - Aphios Corporation - Ausio Pharmaceuticals, LLC - Biolab Sanus Farmaceutica Ltda. - Chong Kun Dang Pharmaceutical Corp. - Corium International, Inc. - Curadis GmbH - Euroscreen S.A. - Hanmi Pharmaceuticals, Co. Ltd. - IntelGenx Corp. - Jeil Pharmaceutical Co., Ltd. - KAEL-GemVax Co., Ltd. - Kaken Pharmaceutical Co., Ltd. - Meiji Seika Pharma Co., Ltd. - Mezzion Pharma Co. Ltd. - Neurocentrx Pharma Ltd. - Nymox Pharmaceutical Corporation - Ono Pharmaceutical Co., Ltd. - Quest PharmaTech Inc. - SK Chemicals Co., Ltd. - SOM Innovation Biotech SL - Sophiris Bio, Inc. - Yungjin Pharm Ind. Co., Ltd. Drug Profiles - (tamsulosin hydrochloride dutasteride) - ADX-68692 - AMV-110 - ASC-JM.X2 - AUS-131 - BL-214 - CKD-902 - CR-1493 - Drugs for Burning Sensation - ESN-364 - HCP-1303 - HIP-1402 - INT-0031 - JLP-1207 - L-1AD3 - MCS-2 - NCE-403 - NX-1207 - ONO-8430506 - S-40542 - SL-052 - Small Molecules to Antagonize GnRH for Women's Health, BPH and Oncology - Small Molecules to Inhibit Steroidal 5-Alpha Reductase for Benign Prostatic Hyperplasia - SOM-2391 - SOM-2393 - Sperol - Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology - talaporfin sodium - tamsulosin hydrochloride - tamsulosin hydrochloride CR - tertomotide - topsalysin - udenafil - YBH-1603 - YOB-1604 For more information visit http://www.researchandmarkets.com/research/k3..._prostatic
CORI: 13.54 (-0.26), SPHS: 0.88 (-0.03), NYMX: 2.61 (+0.04), ABBV: 71.32 (+0.09)
Nymox Announces $850,000 Financing
GlobeNewswire - Tue Jun 16, 11:11AM CDT
Nymox Pharmaceutical Corporation (Nasdaq:NYMX) is pleased to announce that it has recently completed financing for a total of $850,000 at prices of $1.25-$1.66. The financing consisted of a private placement of 400,000 shares with a European investor at $1.25 per share and an equity line drawdown from the Company's existing facility consisting of 217,122 shares priced at $1.66 per share. There were no warrants attached to the transactions.
NYMX: 2.61 (+0.04)
BUYINS.NET: NYMX Removed From Naked Short Lists Today
M2 - Mon May 25, 9:25AM CDT
BUYINS.NET, www.buyins.net , announced today that these select companies have been Removed From the NASDAQ, AMEX, NYSE, OTCBB and Pinksheet naked short threshold lists. Nymox Pharmaceutical Corp (NASDAQ:NYMX). For a complete list of companies on the naked short lists please visit our web site. To find the SqueezeTrigger Price before a short squeeze starts in any stock, go to http://www.buyins.net .
NYMX: 2.61 (+0.04)
BUYINS.NET: NYMX Added To Naked Short Lists Today
M2 - Mon May 18, 9:32AM CDT
BUYINS.NET, www.buyins.net , announced today that these select companies have been Added To the NASDAQ, AMEX, NYSE, OTCBB and Pinksheet naked short threshold lists. Nymox Pharmaceutical Corp (NASDAQ:NYMX). For a complete list of companies on the naked short lists please visit our web site. To find the SqueezeTrigger Price before a short squeeze starts in any stock, go to http://www.buyins.net .
NYMX: 2.61 (+0.04)
Nymox Pharma reports Q1 results
Seeking Alpha - at Seeking Alpha - Fri May 15, 4:45PM CDT
NYMX: 2.61 (+0.04)
Nymox Reports First Quarter 2015 Financial Results
GlobeNewswire - Fri May 15, 4:32PM CDT
Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today its financial results for the first quarter of 2015 prepared in accordance with International Financial Reporting Standards. Nymox reported a net income of $1,576,551, or $0.04 per share for the quarter ended March 31, 2015, compared to a net loss of $2,592,816, or $0.07 per share for same period in 2014. The net income in 2015 is attributable to the recognition of $2,508,533 as revenue relating to the upfront payment received from Recordati in December 2010 compared with $654,400 for the quarter ended March 31, 2014. The increase of $1,854,133 in the first quarter of 2015 is due to the fact that the initial estimated service period of five years to recognize the upfront payment was modified following Recordati's termination of the European clinical trial. Consequently, the Corporation recognized, as revenue, an amount of $2,508,533 which represented the remaining deferred revenue relating to the upfront payment received in December 2010.
NYMX: 2.61 (+0.04)
Midday Gainer / Losers
Seeking Alpha - at Seeking Alpha - Thu May 14, 11:45AM CDT
KNDI: 7.23 (+0.10), INVE: 4.33 (+0.04), JONE: 7.55 (+0.18), QKLS: 1.80 (-0.04), HIIQ: 4.57 (+0.07), NYMX: 2.61 (+0.04), EGAN: 4.41 (-0.12), GEVO: 2.21 (+0.15), HNR: 1.15 (+0.03), FES: 1.12 (+0.04), ONTY: 3.50 (-0.01), GLPG: 56.92 (+1.18), OHGI: 2.14 (+0.04), ATOS: 0.99 (+0.03), CLVS: 84.90 (-1.84), PSTR: 2.12 (+0.18), AKER: 4.33 (+0.09), RVNC: 31.79 (-0.91), GIGA: 1.66 (-0.18), DSCO: 0.55 (+0.02)
Consumers Growing Interest in a Healthy Lifestyle Leads to Increase in Nutritional Supplement Revenues as Distribution Channels Open Up in North America
PR Newswire - Tue May 12, 7:25AM CDT
Consumers across various age groups are leading a healthier life by eating right, exercising and consuming supplements to meet their recommended dietary allowances. Nutritional supplements are readily available at a growing number of stores and fitness centers that enable consumers to stay healthy as Companies look for innovative ways to increase distribution on a Global level. Companies in focus today are: Axxess Pharma Inc. (OTC: AXXE), Vitamin Shoppe, Inc. (NYSE: VSI), Nymox Pharmaceutical Corporation (NASDAQ: NYMX), MusclePharm Corporation (OTC: MSLP) and Natural Health Trends Corp. (NASDAQ: NHTC)
VSI: 35.17 (+0.57), NHTC: 34.77 (+10.05), WWE: 16.29 (-0.14), NYMX: 2.61 (+0.04)
Recent Highlights from the Healthcare Sector: Complementary Research on BioMarin, Seattle Genetics, Globus Medical, Nymox and Progenics
PR Newswire - Mon May 11, 7:50AM CDT
Editor Note: For more information about this release, please scroll to bottom.
PGNX: 8.82 (-0.60), BMRN: 142.95 (-2.99), GMED: 27.34 (+0.05), SGEN: 47.30 (-1.63), NYMX: 2.61 (+0.04)
Pharma Companies Beginning to Mix Diversification by Expanding into the Multi-Billion Dollar Nutritional & Nutraceutical Supplements Market as Projected Growth Opportunities Continue to Rise
PR Newswire - Wed May 06, 7:45AM CDT
Global pharmaceutical market moves beyond traditional prescription-only medicines as the nutritional sector for weight management, sports nutrition and additional supplements & nutraceuticals accelerate with International growth opportunities. Pharma Companies in focus today are: Axxess Pharma Inc. (OTC: AXXE), Nymox Pharmaceutical Corporation (NASDAQ: NYMX), AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG), NuVasive, Inc. (NASDAQ: NUVA) and Mylan N.V. (NASDAQ: MYL).
WWE: 16.29 (-0.14), MYL: 56.81 (+0.46), AMAG: 64.71 (-1.52), NYMX: 2.61 (+0.04), NUVA: 54.59 (+4.12)
Nasdaq stocks posting largest volume increases
AP - Tue Apr 21, 5:03PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
FARO: 38.71 (+0.18), ENZN: 1.45 (+0.11), CDZI: 8.40 (-0.56), BNSO: 1.24 (-0.06), DTLK: 7.06 (+0.22), NYMX: 2.61 (+0.04), IDSY: 5.26 (+0.05), VLTC: 7.08 (-0.41), TLOG: 2.49 (+0.07), UCTT: 7.43 (+0.13), OBAS: 7.31 (-0.19)
Nymox Pharmaceuticals (NYMX) Stock Drops Today Following Monday's Climb
at The Street - Tue Apr 21, 10:25AM CDT
Shares of Nymox Pharmaceuticals (NYMX) were down in late morning trading Tuesday as investors took some profits following the stock's surge on Monday.
NYMX: 2.61 (+0.04)
Nymox Pharmaceuticals (NYMX) Stock Spikes Today on Prostate Cancer Trial Data
at The Street - Mon Apr 20, 11:11AM CDT
Shares of Nymox Pharmaceuticals (NYMX) surged Monday after the company announced long-term clinical trial results from its NX-1207 Phase 2 prostate cancer study NX03-0040.
NYMX: 2.61 (+0.04)
Nymox Pharma's NX-1207 shows long-term benefits in prostate cancer; Shares jump
Seeking Alpha - at Seeking Alpha - Mon Apr 20, 10:08AM CDT
NYMX: 2.61 (+0.04)
Nymox Announces New Prostate Cancer Clinical Trial Results
GlobeNewswire - Mon Apr 20, 9:00AM CDT
Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today long-term clinical trial results from the Company's NX-1207 Phase 2 prostate cancer study NX03-0040. The new results demonstrate statistically significant (p=.0067) better outcomes at up to 2.8 years for NX-1207 treated patients compared to controls. Trial participants included 146 patients with low grade localized prostate cancer at 44 U.S. investigational sites.
NYMX: 2.61 (+0.04)
Nymox Pharmaceutical (NYMX) Stock Higher on Positive Test Results
at The Street - Tue Jul 28, 11:44AM CDT
Nymox Pharmaceutical (NYMX) shares continue to climb on promising BPH treatment candidate results.
NYMX: 2.61 (+0.04)
Nymox July 27 Webcast of New BPH Clinical Trial Results Posted Today Online
GlobeNewswire - Tue Jul 28, 11:00AM CDT
Nymox's (NASDAQ:NYMX) July 27 webcast of news and discussion by experts of the Company's new clinical trial results can be viewed at http://limelightdc.com/clientarea/nymox_inves...r_vod.html. The link is also available at the Company's website.
NYMX: 2.61 (+0.04)
Nymox Pivotal Phase 3 NX-1207 BPH Extension Trial Successfully Meets Primary Endpoint. Company Plans to File for Regulatory Approvals for Fexapotide Triflutate (NX-1207).
GlobeNewswire - Mon Jul 27, 8:30AM CDT
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) announced today that the Company's U.S. long-term extension prospective double-blind Phase 3 BPH studies NX02-0017 and NX02-0018 of fexapotide triflutate (NX-1207) for BPH have successfully met the pre-specified primary endpoint of long-term symptomatic statistically significant benefit superior to placebo. Fexapotide showed an excellent safety profile with no evidence of drug-related short-term or long-term toxicity nor any significant related molecular side effects in the 2 studies (n=978).
NYMX: 2.61 (+0.04)
Nymox Appoints Cutler & Co. as Auditor
GlobeNewswire - Thu Jul 16, 5:03PM CDT
On July 15, 2015, the Board of Directors of Nymox Pharmaceutical Corporation (NASDAQ:NYMX) approved the engagement of Cutler & Co., LLC to serve as the Company's new independent registered public accounting firm to replace KPMG LLP. Prior to the date of Cutler's engagement, the Company has not consulted with Cutler regarding (i) the application of accounting principles to a specific completed or contemplated transaction, (ii) the type of audit opinion that might be rendered on the Company's financial statements and neither a written report was provided to the registrant nor oral advice was provided that the new accountant concluded was an important factor considered by the registrant in reaching a decision as to the accounting, auditing or financial reporting issue; or (iii) any matter that was either the subject of a disagreement.
NYMX: 2.61 (+0.04)
Nymox Announces Appointment of Erik Danielsen as CFO
GlobeNewswire - Mon Jul 13, 12:15PM CDT
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce the appointment of Erik Danielsen as Chief Financial Officer of the Company. Mr. Danielsen is a highly experienced financial analyst with special expertise in emerging health care companies, and with extensive international business knowledge.
NYMX: 2.61 (+0.04)
Benign Prostatic Hyperplasia Pipeline Report 2015 - 26 Companies & 35 Drug Profiles
M2 - Fri Jul 10, 3:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/k3hn53/benign_prostatic) has announced the addition of the "Benign Prostatic Hyperplasia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Benign Prostatic Hyperplasia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Benign Prostatic Hyperplasia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Addex Therapeutics Ltd - AmVac AG - AndroScience Corporation - Aphios Corporation - Ausio Pharmaceuticals, LLC - Biolab Sanus Farmaceutica Ltda. - Chong Kun Dang Pharmaceutical Corp. - Corium International, Inc. - Curadis GmbH - Euroscreen S.A. - Hanmi Pharmaceuticals, Co. Ltd. - IntelGenx Corp. - Jeil Pharmaceutical Co., Ltd. - KAEL-GemVax Co., Ltd. - Kaken Pharmaceutical Co., Ltd. - Meiji Seika Pharma Co., Ltd. - Mezzion Pharma Co. Ltd. - Neurocentrx Pharma Ltd. - Nymox Pharmaceutical Corporation - Ono Pharmaceutical Co., Ltd. - Quest PharmaTech Inc. - SK Chemicals Co., Ltd. - SOM Innovation Biotech SL - Sophiris Bio, Inc. - Yungjin Pharm Ind. Co., Ltd. Drug Profiles - (tamsulosin hydrochloride dutasteride) - ADX-68692 - AMV-110 - ASC-JM.X2 - AUS-131 - BL-214 - CKD-902 - CR-1493 - Drugs for Burning Sensation - ESN-364 - HCP-1303 - HIP-1402 - INT-0031 - JLP-1207 - L-1AD3 - MCS-2 - NCE-403 - NX-1207 - ONO-8430506 - S-40542 - SL-052 - Small Molecules to Antagonize GnRH for Women's Health, BPH and Oncology - Small Molecules to Inhibit Steroidal 5-Alpha Reductase for Benign Prostatic Hyperplasia - SOM-2391 - SOM-2393 - Sperol - Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology - talaporfin sodium - tamsulosin hydrochloride - tamsulosin hydrochloride CR - tertomotide - topsalysin - udenafil - YBH-1603 - YOB-1604 For more information visit http://www.researchandmarkets.com/research/k3..._prostatic
CORI: 13.54 (-0.26), SPHS: 0.88 (-0.03), NYMX: 2.61 (+0.04), ABBV: 71.32 (+0.09)
Nymox Announces $850,000 Financing
GlobeNewswire - Tue Jun 16, 11:11AM CDT
Nymox Pharmaceutical Corporation (Nasdaq:NYMX) is pleased to announce that it has recently completed financing for a total of $850,000 at prices of $1.25-$1.66. The financing consisted of a private placement of 400,000 shares with a European investor at $1.25 per share and an equity line drawdown from the Company's existing facility consisting of 217,122 shares priced at $1.66 per share. There were no warrants attached to the transactions.
NYMX: 2.61 (+0.04)
BUYINS.NET: NYMX Removed From Naked Short Lists Today
M2 - Mon May 25, 9:25AM CDT
BUYINS.NET, www.buyins.net , announced today that these select companies have been Removed From the NASDAQ, AMEX, NYSE, OTCBB and Pinksheet naked short threshold lists. Nymox Pharmaceutical Corp (NASDAQ:NYMX). For a complete list of companies on the naked short lists please visit our web site. To find the SqueezeTrigger Price before a short squeeze starts in any stock, go to http://www.buyins.net .
NYMX: 2.61 (+0.04)
BUYINS.NET: NYMX Added To Naked Short Lists Today
M2 - Mon May 18, 9:32AM CDT
BUYINS.NET, www.buyins.net , announced today that these select companies have been Added To the NASDAQ, AMEX, NYSE, OTCBB and Pinksheet naked short threshold lists. Nymox Pharmaceutical Corp (NASDAQ:NYMX). For a complete list of companies on the naked short lists please visit our web site. To find the SqueezeTrigger Price before a short squeeze starts in any stock, go to http://www.buyins.net .
NYMX: 2.61 (+0.04)
Nymox Pharma reports Q1 results
Seeking Alpha - at Seeking Alpha - Fri May 15, 4:45PM CDT
NYMX: 2.61 (+0.04)
Nymox Reports First Quarter 2015 Financial Results
GlobeNewswire - Fri May 15, 4:32PM CDT
Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today its financial results for the first quarter of 2015 prepared in accordance with International Financial Reporting Standards. Nymox reported a net income of $1,576,551, or $0.04 per share for the quarter ended March 31, 2015, compared to a net loss of $2,592,816, or $0.07 per share for same period in 2014. The net income in 2015 is attributable to the recognition of $2,508,533 as revenue relating to the upfront payment received from Recordati in December 2010 compared with $654,400 for the quarter ended March 31, 2014. The increase of $1,854,133 in the first quarter of 2015 is due to the fact that the initial estimated service period of five years to recognize the upfront payment was modified following Recordati's termination of the European clinical trial. Consequently, the Corporation recognized, as revenue, an amount of $2,508,533 which represented the remaining deferred revenue relating to the upfront payment received in December 2010.
NYMX: 2.61 (+0.04)
Midday Gainer / Losers
Seeking Alpha - at Seeking Alpha - Thu May 14, 11:45AM CDT
KNDI: 7.23 (+0.10), INVE: 4.33 (+0.04), JONE: 7.55 (+0.18), QKLS: 1.80 (-0.04), HIIQ: 4.57 (+0.07), NYMX: 2.61 (+0.04), EGAN: 4.41 (-0.12), GEVO: 2.21 (+0.15), HNR: 1.15 (+0.03), FES: 1.12 (+0.04), ONTY: 3.50 (-0.01), GLPG: 56.92 (+1.18), OHGI: 2.14 (+0.04), ATOS: 0.99 (+0.03), CLVS: 84.90 (-1.84), PSTR: 2.12 (+0.18), AKER: 4.33 (+0.09), RVNC: 31.79 (-0.91), GIGA: 1.66 (-0.18), DSCO: 0.55 (+0.02)
Consumers Growing Interest in a Healthy Lifestyle Leads to Increase in Nutritional Supplement Revenues as Distribution Channels Open Up in North America
PR Newswire - Tue May 12, 7:25AM CDT
Consumers across various age groups are leading a healthier life by eating right, exercising and consuming supplements to meet their recommended dietary allowances. Nutritional supplements are readily available at a growing number of stores and fitness centers that enable consumers to stay healthy as Companies look for innovative ways to increase distribution on a Global level. Companies in focus today are: Axxess Pharma Inc. (OTC: AXXE), Vitamin Shoppe, Inc. (NYSE: VSI), Nymox Pharmaceutical Corporation (NASDAQ: NYMX), MusclePharm Corporation (OTC: MSLP) and Natural Health Trends Corp. (NASDAQ: NHTC)
VSI: 35.17 (+0.57), NHTC: 34.77 (+10.05), WWE: 16.29 (-0.14), NYMX: 2.61 (+0.04)
Recent Highlights from the Healthcare Sector: Complementary Research on BioMarin, Seattle Genetics, Globus Medical, Nymox and Progenics
PR Newswire - Mon May 11, 7:50AM CDT
Editor Note: For more information about this release, please scroll to bottom.
PGNX: 8.82 (-0.60), BMRN: 142.95 (-2.99), GMED: 27.34 (+0.05), SGEN: 47.30 (-1.63), NYMX: 2.61 (+0.04)
Pharma Companies Beginning to Mix Diversification by Expanding into the Multi-Billion Dollar Nutritional & Nutraceutical Supplements Market as Projected Growth Opportunities Continue to Rise
PR Newswire - Wed May 06, 7:45AM CDT
Global pharmaceutical market moves beyond traditional prescription-only medicines as the nutritional sector for weight management, sports nutrition and additional supplements & nutraceuticals accelerate with International growth opportunities. Pharma Companies in focus today are: Axxess Pharma Inc. (OTC: AXXE), Nymox Pharmaceutical Corporation (NASDAQ: NYMX), AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG), NuVasive, Inc. (NASDAQ: NUVA) and Mylan N.V. (NASDAQ: MYL).
WWE: 16.29 (-0.14), MYL: 56.81 (+0.46), AMAG: 64.71 (-1.52), NYMX: 2.61 (+0.04), NUVA: 54.59 (+4.12)
Nasdaq stocks posting largest volume increases
AP - Tue Apr 21, 5:03PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
FARO: 38.71 (+0.18), ENZN: 1.45 (+0.11), CDZI: 8.40 (-0.56), BNSO: 1.24 (-0.06), DTLK: 7.06 (+0.22), NYMX: 2.61 (+0.04), IDSY: 5.26 (+0.05), VLTC: 7.08 (-0.41), TLOG: 2.49 (+0.07), UCTT: 7.43 (+0.13), OBAS: 7.31 (-0.19)
Nymox Pharmaceuticals (NYMX) Stock Drops Today Following Monday's Climb
at The Street - Tue Apr 21, 10:25AM CDT
Shares of Nymox Pharmaceuticals (NYMX) were down in late morning trading Tuesday as investors took some profits following the stock's surge on Monday.
NYMX: 2.61 (+0.04)
Nymox Pharmaceuticals (NYMX) Stock Spikes Today on Prostate Cancer Trial Data
at The Street - Mon Apr 20, 11:11AM CDT
Shares of Nymox Pharmaceuticals (NYMX) surged Monday after the company announced long-term clinical trial results from its NX-1207 Phase 2 prostate cancer study NX03-0040.
NYMX: 2.61 (+0.04)
Nymox Pharma's NX-1207 shows long-term benefits in prostate cancer; Shares jump
Seeking Alpha - at Seeking Alpha - Mon Apr 20, 10:08AM CDT
NYMX: 2.61 (+0.04)
Nymox Announces New Prostate Cancer Clinical Trial Results
GlobeNewswire - Mon Apr 20, 9:00AM CDT
Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today long-term clinical trial results from the Company's NX-1207 Phase 2 prostate cancer study NX03-0040. The new results demonstrate statistically significant (p=.0067) better outcomes at up to 2.8 years for NX-1207 treated patients compared to controls. Trial participants included 146 patients with low grade localized prostate cancer at 44 U.S. investigational sites.
NYMX: 2.61 (+0.04)
